Firms ally to develop drug for cancer, autoimmune disease

05/17/2013 | Genetic Engineering & Biotechnology News

RuiYi and Genor Biopharma agreed to co-develop the former's experimental monoclonal antibody drug RYI-008 against cancer and autoimmune diseases, particularly rheumatoid arthritis, in China. The deal follows RuiYi's announcement that it would use CMC Biologics' CHEF1 high-productivity expression plasmid to speed work on a cell line for RYI-008.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN